3 January 2023
IXICO plc
("IXICO" or the "Company")
Total Voting Rights
In accordance with section 5.6.1 of the Financial Conduct Authority's (FCA) Disclosure Guidance and Transparency Rules (DTRs), the Group hereby notifies the market of the following:
The Group's issued capital as at 31 December 2022, consists of 48,351,373 ordinary shares of £0.01 each (Ordinary Shares) with voting rights attached. Of these, no Ordinary Shares are held exclusive of voting rights in Treasury.
Therefore, the total number of voting rights in IXICO as at 31 December 2022 is 48,351,373.
Shareholders may use the figure of 48,351,373 Ordinary Shares as the denominator for the calculations by which they will determine if they are required to notify their interest, or a change to their interest, in IXICO under the DTRs.
For further information please contact:
| IXICO plc | +44 (0)20 3763 7499 | |
| Giulio Cerroni, Chief Executive Officer Grant Nash, Chief Financial Officer |
| |
| |
| |
| Cenkos Securities PLC (Nominated adviser and sole broker) | +44 (0)20 7397 8900 | |
| Giles Balleny / Max Gould (Corporate Finance) | | |
| Michael F Johnson / Tamar Cranford-Smith (Sales) | | |
| | | |
IXICO is dedicated to delivering insights in neuroscience to help transform the advancement of investigational therapies for neurological diseases, such as Huntington's, Parkinson's, Alzheimer's disease and Multiple Sclerosis. The Company's purpose is to advance medicine and human health by turning data into clinically meaningful information, providing valuable new insights in neuroscience by supporting pharmaceutical companies across all phases of CNS clinical research. IXICO's goal is to be a leading advocate of artificial intelligence in medical image analysis.
IXICO has developed and deployed breakthrough machine learning AI data analytics, at scale, through its remote access TrialTracker technology platform, to improve the return on investment in drug development and reduce risk and uncertainty in clinical trials for the Company's pharmaceutical clients.
More information is available on www.IXICO.com and follow us on Twitter @IXICOnews
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.